Discontinuation of medication due to adverse events · people with chronic hepatitis C
Peginterferon plus ribavirin showed no clear difference in adverse events leading to treatment discontinuation compared with non‐pegylated interferon plus ribavirin (low certainty).
1 finding from 1 review
Sustained virological response · people with chronic hepatitis C
It is very uncertain whether peginterferon plus ribavirin changes sustained virological response compared with non‐pegylated interferon plus ribavirin (very low certainty).
1 finding from 1 review
1‐year mortality · previously untreated patients with mRCC
Interferon‐α alone showed no clear difference in 1‐year mortality compared with interferon‐α plus bevacizumab (low certainty).
1 finding from 1 review
Quality of life · previously untreated patients with mRCC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (grade ≥ 3) · previously untreated patients with mRCC
Interferon‐α alone probably leads to lower adverse events (grade ≥ 3) compared with interferon‐α plus bevacizumab (moderate certainty).
1 finding from 1 review
Remission · patients with induction of remission in ulcerative colitis
Type I Interferons showed no clear difference in remission compared with placebo (moderate certainty).
1 finding from 1 review
Clinical improvement · patients with induction of remission in ulcerative colitis
Type I Interferons showed no clear difference in clinical improvement compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · patients with induction of remission in ulcerative colitis
Type I Interferons showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with induction of remission in ulcerative colitis
Type I Interferons may leads to higher withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Relapse · Multiple sclerosis
It is very uncertain whether statins plus beta interferon changes number of participants with relapses at 12 months Number of… compared with beta interferon (very low certainty).
2 findings from 1 review
Number of participants with progression at 12 months3 ‐ not reported · Multiple sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
Number of participants with progression at 24 months Number of participants with progression at 24 months · Multiple sclerosis
It is very uncertain whether statins plus beta interferon changes number of participants with progression at 24 months Number of… compared with beta interferon (very low certainty).
1 finding from 1 review
Number of participants with new T2 or GELs at 12 months Number of participants with new T2 or GELs at 12 months · Multiple sclerosis
It is very uncertain whether statins plus beta interferon changes number of participants with new T2 or GELs at 12 months Number of… compared with beta interferon (very low certainty).
1 finding from 1 review
Number of participants with new T2 or GELs at 24 months3 ‐ not reported · Multiple sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
Change in disability Assessed by: EDSS · Multiple sclerosis
1 finding from 1 review
Sustained virological response · patients on HD with HCV infection
Pegylated interferon alpha‐2a showed no clear difference in sustained virological response 6 months after stopping treatment compared with standard interferon (low certainty).
1 finding from 1 review
Treatment discontinuation · patients on HD with HCV infection
Pegylated interferon alpha‐2a showed no clear difference in treatment discontinuation compared with standard interferon (low certainty).
1 finding from 1 review
Adverse events · patients on HD with HCV infection
Pegylated interferon alpha‐2a showed no clear difference in adverse events compared with standard interferon (low certainty).
1 finding from 1 review
Death · patients on HD with HCV infection
Pegylated interferon alpha‐2a showed no clear difference in death compared with standard interferon (low certainty).
1 finding from 1 review
Relapse Number of participants having recurrence after stopping · patients on HD with HCV infection
Pegylated interferon alpha‐2a showed no clear difference in relapse(recurrence after stopping) compared with standard interferon (low certainty).
1 finding from 1 review